VIR - NASDAQ
Vir Biotechnology, Inc.
$8.77
+0.34%Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with The Rockefeller University and MedImmune, Inc.; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.
At a Glance
Live Snapshotvir
Total Non-Current Assets
Last Annual Value
488.74M
3-Year CAGR
20%
5-Year CAGR
27%
10-Year CAGR
23%
Vir Biotechnology, Inc. Competitors Analysis of Total Non-Current Assets
| Company | Total Non-Current Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
Vir Biotechnology, Inc. NASDAQ:VIR | 488.74M | 13.9% | 4.5% | N/A | |
 Maravai LifeSciences Holdings, Inc. NASDAQ:MRVI | 474.33M | -15.5% | -16.6% | N/A | |
 Iovance Biotherapeutics, Inc. NASDAQ:IOVA | 470.48M | -0.1% | 11.8% | 69.7% | |
 Prime Medicine, Inc. NASDAQ:PRME | 161.44M | 46.9% | 38.9% | N/A | |
 Geron Corporation NASDAQ:GERN | 50.27M | -1.6% | 5.3% | 13.5% | |
 LENZ Therapeutics, Inc. NASDAQ:LENZ | 13.53M | 62.9% | 307.8% | N/A | |
 Day One Biopharmaceuticals, Inc. NASDAQ:DAWN | 22.73M | 208.5% | 118.8% | N/A | |
 Ginkgo Bioworks Holdings, Inc. NYSE:DNA | 647.86M | -0.8% | 13.2% | N/A | |
 Kura Oncology, Inc. NASDAQ:KURA | 29.70M | 21.8% | 20.4% | 40.2% | |
 Replimune Group, Inc. NASDAQ:REPL | 55.45M | 0.9% | -1.4% | N/A |
Vir Biotechnology, Inc. Fair Value Envelope
Related Guides
Continue your VIR research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.